Anthropic is launching an internal drug discovery program focused on neglected diseases, the company announced Tuesday in San Francisco, alongside a new product called Claude Science designed for pharmaceutical companies. The move puts the artificial intelligence startup directly into the healthcare arena, joining other tech giants that have spent years trying to crack the drug development market with mixed results.
The company's life sciences head Eric Kauderer-Abrams said Anthropic will target diseases that traditional biopharmaceutical companies consider unattractive - conditions where the commercial payoff doesn't justify the research investment. "We're doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you," Kauderer-Abrams said. "We believe in the power of tight feedback loops, and there's no substitute for having our own experiences alongside you all in the trenches trying to develop drugs."
Anthropic did not specify what it would do with any promising drug candidates it discovers. Traditional drugmakers would typically advance such candidates into clinical trials, a process Anthropic has not outlined. A company spokesperson told CNBC that as a public benefit company, "we can choose programs on patient benefit, including work the commercial market overlooks." The spokesperson added: "We're at the start of this, and we'll share more as the work progresses."
The public benefit company advantage
Anthropic's structure as a public benefit corporation gives it legal room to prioritize patient outcomes over profit - a distinction that traditional pharmaceutical companies, beholden to shareholders, cannot easily make. This framing allows the company to pursue drug targets that might never generate blockbuster returns but could still address serious unmet medical needs.
Jonah Cool, Anthropic's head of life sciences partnerships, positioned the drug discovery work as complementary to the company's commercial ambitions. The goal, he said, is to focus on neglected diseases while creating and selling AI tools for life sciences companies. The parallel effort is meant to build credibility with the very drugmakers Anthropic hopes will adopt its new Claude Science platform.
Tech's long history with healthcare
Anthropic is not the first technology company to bet on healthcare. Alphabet has invested in life sciences through subsidiaries like Verily and Calico. Apple has built health-tracking capabilities into its devices. Amazon acquired One Medical and PillPack, now operating under Amazon Health Services. These efforts have produced uneven results - healthcare's regulatory complexity, long development timelines, and fragmented data systems have frustrated many Silicon Valley entrants.
The announcement came as Anthropic CEO Dario Amodei attended the G7 Summit in Évian-les-Bains, France, earlier in June, where global leaders discussed AI and innovation with top technology executives. The company's push into drug discovery signals that AI firms see healthcare not just as a market for their tools, but as a domain where they intend to be direct participants.
Why this matters for healthcare professionals
For professionals in the healthcare and life sciences sectors, Anthropic's entry into drug discovery marks a shift in how AI companies approach the industry. Rather than simply selling software to pharma companies, AI firms are now building their own drug development pipelines - which could create new partnership opportunities, competitive pressures, or collaborative models. The focus on neglected diseases also suggests that AI-driven discovery may open therapeutic areas that traditional commercial incentives have left untouched. Healthcare leaders should watch how Anthropic's internal programs evolve and whether the company's AI for Healthcare tools gain traction among established drugmakers. The tight feedback loop between internal research and product development may accelerate the capabilities of AI for Science & Research in ways that ripple across the entire drug development ecosystem.
Your membership also unlocks:
